Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Verena TschollAbdullah Khaled-A LsharafTina LinBarbara BellmannPatrick NagelKlaus LenzUlf LandmesserMattias RoserAndreas RilligPublished in: Clinical cardiology (2017)
Apixaban, rivaroxaban, and dabigatran, compared with uninterrupted VKA, did not show a higher risk for major bleeding or ischemic complications in patients undergoing PVI using the second-generation CB.
Keyphrases
- atrial fibrillation
- catheter ablation
- patients undergoing
- left atrial
- left atrial appendage
- oral anticoagulants
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- venous thromboembolism
- cerebral ischemia
- oxidative stress
- brain injury
- left ventricular
- blood brain barrier
- subarachnoid hemorrhage
- radiofrequency ablation